[1]焦 燕,夏海龙,张舒颖.全身炎症反应指数对多发性骨髓瘤患者疗效及预后的评估价值[J].医学信息,2024,37(05):96-101.[doi:10.3969/j.issn.1006-1959.2024.05.016]
　JIAO Yan,XIA Hai-long,ZHANG Shu-ying.Value of Systemic Inflammation Response Index for the Efficacy and Prognostic Evaluation of Multiple Myeloma Patients[J].Journal of Medical Information,2024,37(05):96-101.[doi:10.3969/j.issn.1006-1959.2024.05.016]
点击复制

全身炎症反应指数对多发性骨髓瘤患者疗效及预后的评估价值()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
37卷
期数:
2024年05期
页码:
96-101
栏目:
论著
出版日期:
2024-03-01

文章信息/Info

Title:
Value of Systemic Inflammation Response Index for the Efficacy and Prognostic Evaluation of Multiple Myeloma Patients
文章编号:
1006-1959（2024）05-0096-06
作者:
焦 燕; 夏海龙; 张舒颖
（1.安徽医科大学附属巢湖医院血液内科，安徽 巢湖 238000；2.安徽医科大学第一附属医院血液内科，安徽 合肥 230022）
Author(s):
JIAO Yan; XIA Hai-long; ZHANG Shu-ying
(1.Department of Hematology,Chaohu Hospital of Anhui Medical University,Chaohu 238000,Anhui,China;2.Department of Hematology,the First Afiliated Hospital of Anhui Medical University,Hefei 230022,Anhui,China)
关键词:
多发性骨髓瘤; 全身炎症反应指数; 中性粒细胞; 单核细胞; 淋巴细胞计数
Keywords:
Multiple myeloma; Systemic inflammatory response index; Neutrophils; Monocytes; Lymphocyte count
分类号:
R733.3
DOI:
10.3969/j.issn.1006-1959.2024.05.016
文献标志码:
A
摘要:
目的 探索全身炎症反应指数（SIRI）在接受PDD方案治疗的初治MM患者疗效和预后中的作用。方法 收集2015年12月-2021年12月接受PDD方案治疗的110例初治MM患者临床资料，通过受试者工作特征曲线计算出最佳截断值，并将患者分为高SIRI组和低SIRI组。通过Kaplan-Meier生存曲线分析两组患者生存时间，采用单因素和多因素Cox回归模型分析初治MM预后的影响因素。结果 ①ROC曲线分析显示，SIRI的最佳截断值为1.03×109/L，其中高SIRI组42例和低SIRI组68例，高SIRI组与低SIRI组年龄、骨髓浆细胞百分比、白蛋白、血清钙比较，差异有统计学意义（P＜0.05）；②治疗4个疗程后，高SIRI组总有效率低于低SIRI组（P＜0.05）；③单因素分析显示，血钙、ISS分期、β2-MG、肌酐、P53缺失、RB1缺失、D13S319缺失、高SIRI是PFS的影响因素（P＜0.05）；高SIRI、β2-MG、肌酐、P53 缺失、D13S319缺失是OS的影响因素（P＜0.05）；④多因素分析显示，高SIRI、RB1缺失、β2-MG是影响PFS的独立危险因素（P＜0.05）；高SIRI、β2-MG是影响OS的独立危险因素（P＜0.05）。结论 SIRI升高是初诊MM患者的独立预后不良因素。
Abstract:
Objective To explore the role of systemic inflammatory response index(SIRI) in the efficacy and prognosis of newly treated MM patients receiving PDD regimen.Methods The clinical data of 110 newly treated MM patients who received PDD regimen from December 2015 to December 2021 were collected, and the best cutoff value was calculated by the working characteristic curve of the subjects, and the patients were divided into high SIRI group and low SIRI group. Kaplan-Meier survival curve was used to analyze the survival time of the two groups. Univariate and multivariate Cox regression models were used to analyze the prognostic factors of newly diagnosed MM.Results ①ROC curve analysis showed that the optimal cut-off value of SIRI was 1.03×109/L, including 42 cases in the high SIRI group and 68 cases in the low SIRI group. There were significant differences in age, percentage of bone marrow plasma cells, albumin and serum calcium between the high SIRI group and the low SIRI group (P<0.05).②After 4 courses of treatment, the total effective rate of the high SIRI group was lower than that of the low SIRI group (P<0.05).③Univariate analysis showed that serum calcium, ISS stage, β2-MG, creatinine, P53 deletion, RB1 deletion, D13S319 deletion and high SIRI were the influencing factors of PFS (P<0.05); high SIRI, β2-MG, creatinine, P53 deletion and D13S319 deletion were the influencing factors of OS(P<0.05).④Multivariate analysis showed that high SIRI, RB1 deletion and β2-MG were independent risk factors for PFS (P<0.05); high SIRI and β2-MG were independent risk factors for OS (P<0.05).Conclusion Increased SIRI is an independent poor prognostic factor in newly diagnosed MM patients.

参考文献/References:

[1]Tamura H.Immunopathogenesis and immunotherapy of multiple myeloma[J].Int J Hematol,2018,107(3):278-285.[2]Dimopoulos MA,Jakubowiak AJ,McCarthy PL,et al.Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma[J].Blood Cancer J,2020,10(2):17.[3]Ma L,Fu C,Liu H,et al.Retrospective study of the efficacy and safety of treatment with PDD vs PAD in de novo patients with multiple myiloma[J].Chinese Journal of Hematology,2015,36(4):340-343.[4]Callander NS,Baljevic M,Adekola K,et al.NCCN Guidelines?誖 Insights: Multiple Myeloma,Version 3.2022[J].J Natl Compr Canc Netw,2022,20(1):8-19.[5]Siegel DS,Dimopoulos MA,Ludwig H,et al.Improvement in Overall Survival With Carfilzomib,Lenalidomide,and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma[J].J Clin Oncol,2018,36(8):728-734.[6]Giannakoulas N,Ntanasis-Stathopoulos I,Terpos E.The Role of Marrow Microenvironment in the Growth and Development of Malignant Plasma Cells in Multiple Myeloma[J].Int J Mol Sci,2021,22(9):4462.[7]de Jong MME,Kellermayer Z,Papazian N,et al.The multiple myeloma microenvironment is defined by an inflammatory stromal cell landscape[J].Nat Immunol,2021,22(6):769-780.[8]Pacheco-Barcia V,Mondéjar Solís R,France T,et al.A systemic inflammation response index (SIRI) correlates with survival and predicts oncological outcome for mFOLFIRINOX therapy in metastatic pancreatic cancer[J].Pancreatology,2020,20(2):254-264.[9]Gao W,Zhang F,Ma T,et al.High Preoperative Fibrinogen and Systemic Inflammation Response Index (F-SIRI) Predict Unfavorable Survival of Resectable Gastric Cancer Patients[J].J Gastric Cancer,2020,20(2):202-211.[10]Wang L,Zhou Y,Xia S,et al.Prognostic value of the systemic inflammation response index (SIRI) before and after surgery in operable breast cancer patients[J].Cancer Biomark,2020,28(4):537-547.[11]Kumar S,Paiva B,Anderson KC,et al.International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma[J].Lancet Oncol,2016,17(8):e328-e346.[12]Qi Q,Zhuang L,Shen Y,et al.A novel systemic inflammation response index (SIRI) for predicting the survival of patients with pancreatic cancer after chemotherapy[J].Cancer,2016,122(14):2158-2167.[13]Singh N,Baby D,Rajguru JP,et al.Inflammation and cancer[J].Ann Afr Med,2019,18(3):121-126.[14]Zhang Y,Xing Z,Zhou K,et al.The Predictive Role of Systemic Inflammation Response Index (SIRI) in the Prognosis of Stroke Patients[J].Clin Interv Aging,2021,16:1997-2007.[15]Wang X,Qiu L,Li Z,et al.Understanding the Multifaceted Role of Neutrophils in Cancer and Autoimmune Diseases[J].Front Immunol,2018,9:2456.[16]Teijeira á,Garasa S,Gato M,et al.CXCR1 and CXCR2 Chemokine Receptor Agonists Produced by Tumors Induce Neutrophil Extracellular Traps that Interfere with Immune Cytotoxicity[J].Immunity,2020,52(5):856-871.e8.[17]Xiong S,Dong L,Cheng L.Neutrophils in cancer carcinogenesis and metastasis[J].J Hematol Oncol,2021,14(1):173.[18]Castaneda CA,Castillo M,Aliaga K,et al.Level of tumor-infiltrating lymphocytes and density of infiltrating immune cells in different malignancies[J].Biomark Med,2019,13(17):1481-1491.[19]Feng F,Zheng G,Wang Q,et al.Low lymphocyte count and high monocyte count predicts poor prognosis of gastric cancer[J].BMC Gastroenterol,2018,18(1):148.[20]Urakawa S,Yamasaki M,Goto K,et al.Peri-operative monocyte count is a marker of poor prognosis in gastric cancer: increased monocytes are a characteristic of myeloid-derived suppressor cells[J].Cancer Immunol Immunother,2019,68(8):1341-1350.[21]杨文慧,孙延庆,张启科,等.中性粒细胞/淋巴细胞比值及单核细胞/淋巴细胞比值在多发性骨髓瘤患者中的预后意义[J].中国实验血液学杂志,2021,29(1):122-130.

相似文献/References:

[1]贾海英,黄睿,王玲玲,等.多发性骨髓瘤患者淋巴细胞亚群变化对免疫功能的影响研究[J].医学信息,2018,31(01):147.[doi:10.3969/j.issn.1006-1959.2018.01.057]
　JIA Hai-ying,HUANG Rui,WANG Ling-ling,et al.The Effect of Lymphocyte Subgroup Changes on Immune Function in Patients with Multiple Myeloma[J].Journal of Medical Information,2018,31(05):147.[doi:10.3969/j.issn.1006-1959.2018.01.057]
[2]黄珍艳.实验室指标对多发性骨髓瘤的诊断价值分析[J].医学信息,2018,31(05):155.[doi:10.3969/j.issn.1006-1959.2018.05.056]
　HUANG Zhen-yan.Diagnostic Value of Laboratory Markers for Multiple Myeloma[J].Journal of Medical Information,2018,31(05):155.[doi:10.3969/j.issn.1006-1959.2018.05.056]
[3]冯江芳.多发性骨髓瘤患者校正血钙的临床分析[J].医学信息,2018,31(10):87.[doi:10.3969/j.issn.1006-1959.2018.10.026]
　FENG Jiang-fang.Clinical Analysis of Corrected Serum Calcium in Patients with Multiple Myeloma[J].Journal of Medical Information,2018,31(05):87.[doi:10.3969/j.issn.1006-1959.2018.10.026]
[4]王 然,孙言非.血清免疫固定电泳、血清蛋白电泳及免疫球蛋白定量对 多发性骨髓瘤的临床诊断价值[J].医学信息,2019,32(11):173.[doi:10.3969/j.issn.1006-1959.2019.11.054]
　WANG Ran,SUN Yan-fei.Clinical Diagnostic Value of Serum Immunofixation Electrophoresis,Serum Protein Electrophoresis and Immunoglobulin Quantification for Multiple Myeloma[J].Journal of Medical Information,2019,32(05):173.[doi:10.3969/j.issn.1006-1959.2019.11.054]
[5]金 英.硼替佐米治疗老年多发性骨髓瘤的效果[J].医学信息,2020,33(06):146.[doi:10.3969/j.issn.1006-1959.2020.06.047]
　JIN Ying.Effect of Bortezomib in the Treatment of Elderly Multiple Myeloma[J].Journal of Medical Information,2020,33(05):146.[doi:10.3969/j.issn.1006-1959.2020.06.047]
[6]覃泽东,夏玉梅,陈 莉,等.多发性骨髓瘤合并颅内浆细胞瘤的临床及影像学特点分析[J].医学信息,2021,34(05):111.[doi:10.3969/j.issn.1006-1959.2021.05.031]
　QIN Ze-dong,XIA Yu-mei,CHEN Li,et al.Analysis of Clinical and Imaging Characteristics of Multiple Myeloma Combined with Intracranial Plasmacytoma[J].Journal of Medical Information,2021,34(05):111.[doi:10.3969/j.issn.1006-1959.2021.05.031]
[7]晏建国,罗 萍,胡 飞,等.多发性骨髓瘤患者EB病毒检测及其临床意义[J].医学信息,2021,34(15):86.[doi:10.3969/j.issn.1006-1959.2021.15.022]
　YAN Jian-guo,LUO Ping,HU Fei,et al.Detection of Epstein-Barr Virus in Patients with Multiple Myeloma and Its Clinical Significance[J].Journal of Medical Information,2021,34(05):86.[doi:10.3969/j.issn.1006-1959.2021.15.022]
[8]李 玲.β2-微球蛋白、C反应蛋白及乳酸脱氢酶检测在多发性骨髓瘤诊治中的价值[J].医学信息,2021,34(16):187.[doi:10.3969/j.issn.1006-1959.2021.16.054]
　LI Ling.The Value of β2-microglobulin,C-reactive Protein and Lactate Dehydrogenase in the Diagnosis and Treatment of Multiple Myeloma[J].Journal of Medical Information,2021,34(05):187.[doi:10.3969/j.issn.1006-1959.2021.16.054]
[9]燕法红,邱志远,李乾鹏,等.激活蛋白-1家族JunB、c-Jun、c-Maf、c-Fos在多发性骨髓瘤中的表达[J].医学信息,2021,34(23):44.[doi:10.3969/j.issn.1006-1959.2021.23.012]
　YAN Fa-hong,QIU Zhi-yuan,LI Qian-peng,et al.Expression of Activator Protein-1 Family JunB,c-Jun,c-Maf,c-Fos in Multiple Myeloma[J].Journal of Medical Information,2021,34(05):44.[doi:10.3969/j.issn.1006-1959.2021.23.012]
[10]邓 娜,吴冠宇,杨 柳,等.流式细胞术在多发性骨髓瘤治疗中的应用价值[J].医学信息,2022,35(02):75.[doi:10.3969/j.issn.1006-1959.2022.02.018]
　DENG Na,WU Guan-yu,YANG Liu,et al.Application Value of Flow Cytometry in the Treatment of Multiple Myeloma[J].Journal of Medical Information,2022,35(05):75.[doi:10.3969/j.issn.1006-1959.2022.02.018]

更新日期/Last Update: 1900-01-01